ImmunoPrecise Antibodies Ltd News - IPA

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer Canada...

ImmunoPrecise Antibodies Announces 95.7% Investors Favored Debenture Extension and Q1 2020 Financial Results

ImmunoPrecise Antibodies Announces 95.7% Investors Favored Debenture Extension and Q1 2020 Financial...

ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therape...

ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel...

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata...

ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million

ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million Canada NewsWire VICTORIA...

ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee Canada...

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals Canada...

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody...

ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's Proprietary High-Thr...

ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's...

ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc ...

ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier...

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference Canada...

ImmunoPrecise Appoints Andy Nixon to Board of Directors

ImmunoPrecise Appoints Andy Nixon to Board of Directors Canada NewsWire VICTORIA, April 11, 2019 VICTORIA...

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeut...

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the...

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics Canada...

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market Canada NewsWire VICTORIA, April...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPA News

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

ImmunoPrecise Antibodies Announces 95.7% Investors Favored Debenture Extension and Q1 2020 Financial Results

ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therape...

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)

ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million

ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's Proprietary High-Thr...

ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc ...

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

ImmunoPrecise Appoints Andy Nixon to Board of Directors

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeut...

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

IPA Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

ImmunoPrecise Antibodies Ltd (IPA) News

ImmunoPrecise Antibodies Ltd (IPA)

Empower your portfolio: Real-time discussions and actionable trading ideas.

IPA News

ImmunoPrecise Antibodies Appoints Biotech Industry Executive Dr. Stefan Lang as Chief Business Officer

ImmunoPrecise Antibodies Announces 95.7% Investors Favored Debenture Extension and Q1 2020 Financial Results

ImmunoPrecise's Talem Therapeutics Enters into an LOI with AgonOx Pharma in the Advancement of Novel, Immuno-Oncology Therape...

ImmunoPrecise Launches Abthena™ Bispecific Platform And Artemis™ Intelligence Metadata (AIM)

ImmunoPrecise Antibodies' Annual Revenues Increase 100% to $10,926,268 Million

ImmunoPrecise's Wholly Owned Talem Therapeutics Announces the Creation of its Scientific Committee

ImmunoPrecise Antibodies Announces Immuno-oncology Discovery Collaboration with Entos Pharmaceuticals

ImmunoPrecise Guarantees Success for Customers of Their Well-Established B cell Select™ Antibody Discovery Platform

ImmunoPrecise Antibodies Announces an Unprecedented Onboarding of Pharma and Biotech Clients Using IPA's Proprietary High-Thr...

ImmunoPrecise Antibodies' Subsidiary U-Protein Express Announces Exclusive Agreement as Global Supplier for Wnt-Surrogate-Fc ...

ImmunoPrecise to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference

ImmunoPrecise Appoints Andy Nixon to Board of Directors

TetraGenetics and ImmunoPrecise extend collaboration by signing multi-target service agreement for the Discovery of Therapeut...

ImmunoPrecise Antibodies Leverages Proprietary Technology and Expertise to Create Talem Therapeutics

ImmunoPrecise Antibodies Ltd. Announces Trading on OTCQB® Venture Market

IPA Discussion

Your Recent History